Tengsheng Pharmaceutical-B (02137) rose more than 9% in the intraday period. As of press release, it was up 5.14% to HK$1.84, with a turnover of HK$4.926,300.
The Zhitong Finance App learned that Tengsheng Pharmaceutical-B (02137) rose more than 9% in the intraday period. As of press release, it had risen 5.14% to HK$1.84, with a turnover of HK$4.9263 million.
According to the news, Tengsheng Pharmaceutical recently announced that it will permanently purchase all rights, ownership and interests in any intellectual property related to BRII-179 (VBI-2601) from VBI Vaccines worldwide.
According to reports, BRII-179 (VBI-2601) is a novel HBV immunotherapy candidate based on recombinant protein. The company believes that it can ensure uninterrupted supply of BRII-179 for clinical development, achieve more efficient BRII-179 production for future commercialization, and maximize the company's future cash flow; believes in the value of BRII-179 in pursuing functional treatment of hepatitis B virus (HBV), and that the company will begin technology from VBI to selected Chinese contract development and manufacturing organizations (CDMO) as soon as possible The need for transfers to control potentially high-demand supply in the future.